PET scan in the staging of non-small cell lung cancer.

[1]  P. Valk,et al.  The impact of PET on the management of lung cancer: the referring physician's perspective. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  M. Boers,et al.  Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial , 2002, The Lancet.

[3]  V Kalff,et al.  (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  G. Hobbs,et al.  Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. , 2001, Chest.

[5]  J. Vansteenkiste,et al.  The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. , 2001, The European respiratory journal.

[6]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[7]  F. Fazio,et al.  18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study. , 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[8]  M. Mandelkern,et al.  Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. , 2000, American journal of clinical oncology.

[9]  R L Wahl,et al.  Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. , 1999, Radiology.

[10]  J Kotzerke,et al.  Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  P C Goodman,et al.  Staging non-small cell lung cancer with whole-body PET. , 1999, Radiology.

[12]  B. Thompson,et al.  PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. , 1999, The Annals of thoracic surgery.

[13]  S. Berlangieri,et al.  F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer. , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[14]  B. Alfano,et al.  Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. , 1999, AJR. American journal of roentgenology.

[15]  M. O'Doherty,et al.  Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. , 1999, The Annals of thoracic surgery.

[16]  T. Turkington,et al.  FDG imaging of lung nodules: a phantom study comparing SPECT, camera-based PET, and dedicated PET. , 1999, Radiology.

[17]  R. Rubens,et al.  Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  G. V. von Schulthess,et al.  Detection of extrathoracic metastases by positron emission tomography in lung cancer. , 1998, The Annals of thoracic surgery.

[19]  P. Rigo,et al.  Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer , 1998, European Journal of Nuclear Medicine.

[20]  J Bogaert,et al.  Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M P Sandler,et al.  Evaluation of benign vs malignant hepatic lesions with positron emission tomography. , 1998, Archives of surgery.

[22]  R. Wahl,et al.  Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. , 1998, Radiology.

[23]  R. Hustinx,et al.  Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  M. Phelps,et al.  Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  K. Nackaerts,et al.  Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer - A prospective analysis of 50 cases , 1997 .

[26]  R. Hustinx,et al.  Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. , 1997, The European respiratory journal.

[27]  K. Nackaerts,et al.  Survival and prognostic factors in resected N2 non-small cell lung cancer: A study of 140 cases , 1997 .

[28]  R. Coleman,et al.  Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. , 1997, AJR. American journal of roentgenology.

[29]  G. V. von Schulthess,et al.  Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. , 1997, Radiology.

[30]  A. Dowlati,et al.  Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. , 1996, The European respiratory journal.

[31]  M. Sasaki,et al.  The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography , 1996, European Journal of Nuclear Medicine.

[32]  R. Whyte,et al.  Distribution of distant metastases from newly diagnosed non-small cell lung cancer. , 1996, The Annals of thoracic surgery.

[33]  K. Pantel,et al.  Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases , 1996, The Lancet.

[34]  J. Sunderland,et al.  Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. , 1996, The Journal of thoracic and cardiovascular surgery.

[35]  A. Dowlati,et al.  Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. , 1996, The European respiratory journal.

[36]  P. Valk,et al.  Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. , 1995, The Annals of thoracic surgery.

[37]  V. Lowe,et al.  Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. , 1995, Chest.

[38]  P. Marsden,et al.  Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer , 1994, The Lancet.

[39]  R. Wahl,et al.  Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. , 1994, Radiology.

[40]  J. Sunderland,et al.  Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1992, Radiology.

[41]  E H Moore,et al.  Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. , 1992, Radiology.

[42]  R. Wahl,et al.  18F‐2‐deoxy‐2‐fluoro‐D‐glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron‐emission tomography , 1991, Cancer.

[43]  B J McNeil,et al.  CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. , 1991, Radiology.

[44]  F. Van de Werf,et al.  Evaluation of the effect of thrombolytic treatment on infarct size and left ventricular function by enzymatic, scintigraphic, and angiographic methods. The European Cooperative Study Group for Recombinant Tissue Type Plasminogen Activator. , 1990, American heart journal.

[45]  T Jones,et al.  Glucose utilization in vivo by human pulmonary neoplasms , 1987, Cancer.

[46]  R. Ginsberg,et al.  Significance of metastatic disease in subaortic lymph nodes. , 1987, The Annals of thoracic surgery.

[47]  E. Hoffman,et al.  Tomographic measurement of local cerebral glucose metabolic rate in humans with (F‐18)2‐fluoro‐2‐deoxy‐D‐glucose: Validation of method , 1979, Annals of neurology.

[48]  Otto Warburn,et al.  THE METABOLISM OF TUMORS , 1931 .

[49]  A. Hogg,et al.  High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[50]  R. Coleman,et al.  FDG PET of pleural effusions in patients with non-small cell lung cancer. , 2000, AJR. American journal of roentgenology.

[51]  F. Maes,et al.  FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? , 1998, European Journal of Nuclear Medicine.

[52]  J. Menten,et al.  Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review. The Leuven Lung Cancer Group. , 1998, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[53]  M. Goldberg,et al.  Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1995, Radiology.

[54]  M. Decramer,et al.  Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients. , 1994, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[55]  M. Reivich,et al.  Labeled 2-deoxy-D-glucose analogs. 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose , 1978 .